Piper Sandler: Deceleration In YoY Growth, High-Ticket Peers Doing Better

Piper Sandler's Q2 performance revealed a mixed picture, with advisory revenue up 12% year-over-year driven by larger deal sizes, though this marked a deceleration from prior periods. Corporate financing declined amid market uncertainty, and fixed income brokerage benefited from a non-recurring transaction, indicating a likely sequential slowdown given anticipated lower Q3 volatility. The mid-market M&A landscape remains challenging, particularly in biotech and with sponsors on the sidelines, prompting a preference for Evercore (EVR) due to its better valuation and positioning for higher-ticket deals and potential tailwinds from a return of sponsor activity.

Analysis

Piper Sandler's (PIPR) Q2 results present a challenging outlook despite positive headline figures. While advisory revenues grew 12% year-over-year, this represents a significant deceleration from the 24% growth recorded for the first half of the year, signaling weakening momentum. The firm's brokerage businesses were buoyed by temporary factors; fixed income performance was driven by a large, non-recurring transaction, and equity brokerage benefited from Q2 market volatility, neither of which are expected to persist into Q3. Core business segments face headwinds, with corporate financing activity (excluding municipals) declining due to market uncertainty. Furthermore, a severe drought in biotech IPOs, where the biopharma economic fee pool has reportedly shrunk by 61%, directly impacts one of PIPR's key franchises. Although the company is investing in talent, with managing directors up 7%, and making strategic acquisitions, it remains exposed to the continued absence of private equity sponsors in the mid-market. In contrast, the analysis suggests Evercore (EVR) is better positioned, benefiting from the current market preference for larger-ticket deals, superior year-over-year growth in advisory, and a more compelling valuation.

Key Decisions for Investors

• Investors should be cautious on Piper Sandler, as its strong Q2 results were inflated by a non-recurring fixed income transaction and transient market volatility, masking decelerating growth in advisory and persistent weakness in its core biotech franchise.
• Consider a relative value strategy favoring Evercore (EVR) over Piper Sandler (PIPR), given EVR's stronger positioning in the large-ticket M&A market, better growth profile, and more attractive relative valuation noted in the report.
• Monitor for a definitive return of private equity sponsor activity and a potential revival in the IPO market, as these are the key catalysts required to reverse the negative trends affecting PIPR's mid-market business.